Question-and-Answer Session
Operator
Thank you. (Operator Instructions). Thank you. Our first question today is coming from [Dan Jaffrey], a Private Investor. Please state your question, sir.
Dan Jaffrey – Private Investor
Yes. I have a few questions, one is do you have any kind of even rough timetable about what will be the next one or two vaccines in your pipeline to enter into clinical trials? And also can you say a few words about the pneumococcal conjugated vaccine, which frankly unless I've missed that, I've never heard off?
Helen G. Yang
Thank you. I'll translate your questions to Mr. Yin. [Foreign Language]
Weidong Yin
[Foreign Language]
Helen G. Yang
So to answer your first question, we're expecting the Japanese encephalitis and rabies vaccines is about to enter into clinical trials, maybe earlier compared to other frontline products. And currently we're having our animal rabies vaccines currently in field trials, which is, because it’s a animal vaccine field trial, its equivalent to clinical trials for human vaccines.
Weidong Yin
[Foreign Language]
Helen G. Yang
And all the above-mentioned products are from the viral vaccines and you’re also asking about the pneumococcal-conjugated vaccine. This is a bacterial vaccine and currently the already launched similar product, as the product generate highest revenue globally for vaccine products. And we’ve already initiated preclinical trial for pneumococcal conjugated vaccine in Sinovac and we expect to file the clinical application in the year of 2011. In order to support the large scale R&D project we’ve already nearly renovated a R&D center in Beijing and this bacterial vaccine R&D platform is also used to develop a HIV vaccine and a meningitis vaccine. And both of these vaccines are also expected to enter into the clinical trails in the next one or two years. And in general for Sinovac, we right now have both the viral vaccine platform and bacterial vaccine platform, which is to support us to conduct the research and development of more human vaccines.
Dan Jaffrey – Private Investor
Can I ask, I don’t want to hog the time, but can I ask an additional question?
Helen G. Yang
Sure.
Dan Jaffrey – Private Investor
What is the status right now of the Anflu vaccine? I understand that the pandemic vaccines have kind of taken the front seat, but I am wondering what is happening with sales and production of your seasonal?
Helen G. Yang
[Foreign Language]
- To read the full transcript on Seeking Alpha, click here »
